Edding Genor Group Holdings Announces Major Licensing Deal, Strategic Partnership Progress, and Potential Buyout Windfall

Date: 4 May 2026

Key Highlights

• Exclusive Global Licensing Deal (Excluding Greater China): Edding Genor Group Holdings Limited (“Edding Genor” or the “Company”, stock code: 6998) has entered into a significant license agreement with TRC 2004, Inc. (later merged into Candid Therapeutics, Inc.), granting an exclusive worldwide license (excluding mainland China, Hong Kong, Macau, and Taiwan) for the development and commercialization of GB261, a differentiated bispecific antibody for B-cell lymphoma and autoimmune diseases.
• Financial Terms Offer Substantial Upside: The Group will receive:
  • Equity participation in the Licensee (Candid Therapeutics, Inc.)
  • A double-digit million US dollar upfront payment
  • Up to US\$443 million in milestone payments
  • Tiered single to double-digit royalties on net sales
• Strategic Merger and Assignment of Rights: In September 2024, Candid Therapeutics merged with TRC 2004, Inc., and in December 2024, the licensing rights and equity participation were transitioned to Candid Therapeutics, consolidating the collaboration and maximizing potential value for Edding Genor.
• Clinical Progress: The partnership has led to the rapid advancement of GB261 in the clinic, including newly initiated studies in rheumatoid arthritis and systemic lupus erythematosus, demonstrating a continuous expansion of its therapeutic footprint.
• Potential Major Windfall via Acquisition: On 3 May 2026, Union Chimique Belge (“UCB”), a leading Belgian pharmaceutical group, announced a definitive agreement to acquire Candid Therapeutics for an upfront payment of US\$2 billion and up to US\$200 million in future milestone payments, subject to closing conditions including anti-trust clearance. The transaction is expected to close by late Q2 or early Q3 2026.

Details for Shareholders: Price-Sensitive Developments

• Equity Stake in Buyout Target: Edding Genor holds an equity interest in Candid Therapeutics as a result of the original license and stock purchase agreements. If the UCB buyout completes, Edding Genor stands to benefit financially, potentially resulting in a significant non-recurring gain.
• Large Upfront and Milestone Payments: The multi-component structure of the deal, including substantial upfront, milestone, and royalty streams, could enhance Edding Genor’s future earnings, cash flow, and valuation.
• Ongoing Clinical Success: Successful trial results and expansion into more autoimmune indications could further increase the asset value of GB261 and the potential for additional royalty income.
• Regulatory and Transaction Risk: The UCB acquisition is still subject to regulatory and customary closing conditions. Shareholders should monitor for updates on the transaction’s completion, as failure or delays could impact expected financial inflows.

About GB261

GB261 is a next-generation bispecific antibody targeting CD3 and CD20, designed for B-cell malignancies and autoimmune diseases. It employs a unique low-affinity CD3 design, which reduces cytokine-release-related safety risks. Phase I/II data have shown an excellent safety profile and a favorable efficacy-safety balance in patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). The product’s differentiated mechanism could position it as a best-in-class therapy within its category.

Board and Leadership

The Board of Directors of Edding Genor Group Holdings Limited is chaired by Mr. Ni Xin, with a mix of executive, non-executive, and independent non-executive directors, ensuring a strong governance structure.

Conclusion: Potential Share Price Catalyst

The combination of an exclusive global out-licensing agreement, participation in a potentially lucrative acquisition by UCB, and strong clinical progress for GB261 constitutes a major value inflection point for Edding Genor. These developments are highly price-sensitive and could have a material impact on the Company’s share price, depending on the ultimate transaction outcome and clinical milestones.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Shareholders and potential investors should conduct their own research and consult independent professional advisors before making investment decisions. The information contained herein is based on the Company’s public disclosures as of 4 May 2026 and may be subject to change.

View EDDING GENOR Historical chart here